Pa. Xarelto Plaintiffs Request to Amend Master Complaint

Introduction

More than 1,800 product liability claims involving Johnson & Johnson and its subsidiary Janssen Pharmaceuticals’ blood thinner Xarelto are awaiting trial in Philadelphia Court of Common Pleas, and trials for three Xarelto lawsuits are expected to begin this April.

A request to make changes to the Master Complaint was put before the Philadelphia Court of Common Pleas by the remaining Pennsylvania plaintiffs to give them time to “reorganize the allegations and provide more details about the actions and inactions that form the bases of already-existing causes of action.” This request is strongly opposed by the defendants.

There are nearly 18,000 Xarelto federal product liability claims consolidated under MDL No.- 2592 in the U.S. District Court for the Eastern District of Louisiana.

Comments

Court Approves $700M Opioid Settlement for Acute Hospitals

Categories: Opioids

A federal court has approved a $700 million class-action settlement that will compensate over 1,000 acute care hospitals for costs related to the opioid crisis.

The settlement consolidates four separate agreements involving major drug…